10/30/2024 | Press release | Archived content
Portfolio company Virica Biotech made two recent collaboration announcements highlighting the industry embracing their cell enhancing platform for improving adeno-associated vectors (AAVs) production. Virica and eXmoor Pharma announced a new collaboration project funded by a joint UK-Canada government initiative. This project aims to enhance the manufacturing of AAVs crucial for gene therapies, ultimately reducing costs and improving the accessibility of life-saving therapies.